Viral drug sensitivity testing using quantitative PCR: Effect of tyrosine kinase inhibitors on polyomavirus BK replication

American Journal of Clinical Pathology

Volumn 134, Issue 6, 2010, Pages 916-920

  Randhawa, Parmjeet S ^a   Farasati, Noush A ^a   Huang, Yuchen ^a   Mapara, Markus Y ^c   Shapiro, Ron ^b  

^a UNIVERSITY OF PITTSBURGH   (United States)

^b UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^c UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

Author keywords

Bk polyomavirus; Infection; Tyrosine kinase

Indexed keywords

DASATINIB; ERLOTINIB; GEFITINIB; IMATINIB; PROTEIN TYROSINE KINASE; PROTEIN VP1; SORAFENIB; SUNITINIB;

ANTIVIRAL ACTIVITY; ANTIVIRAL SUSCEPTIBILITY; ARTICLE; BK VIRUS; CELL CULTURE; CONTROLLED STUDY; DRUG BLOOD LEVEL; ENZYME INHIBITION; GENE AMPLIFICATION; HUMAN; MAJOR CLINICAL STUDY; NONHUMAN; POLYMERASE CHAIN REACTION; POLYOMAVIRUS INFECTION; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; VIRUS GENE; VIRUS INHIBITION; VIRUS REPLICATION;

ANTIVIRAL AGENTS; BK VIRUS; CAPSID PROTEINS; DNA, VIRAL; HUMANS; MICROBIAL SENSITIVITY TESTS; POLYMERASE CHAIN REACTION; PROTEIN KINASE INHIBITORS; VIRUS REPLICATION;

EID: 78649651505     PISSN: 00029173     EISSN: 19437722     Source Type: Journal    
DOI: 10.1309/AJCP7JYHJN1PGQVC     Document Type: Article

References (24)

1. Ferrazzi E, Peracchi M, Biasolo MA, et al. Antiviral activity of gyrase inhibitors norfloxacin, coumermycin A1 and nalidixic acid. Biochem Pharmacol. 1988;37:1885-1886.
2. Pietropaolo V, Degener AM, Di Taranto C, et al. The in vitro effect of monensin on BK polyomavirus replication. New Microbiol. 1995;18:341-349.
3. Schnepf N, Boiteau N, Petit F, et al. Rapid determination of antiviral drug susceptibility of human cytomegalovirus by real-time PCR. Antiviral Res. 2009;81:64-67.
4. Isegawa Y, Takemoto M, Yamanishi K, et al. Real-time PCR determination of human herpesvirus 6 antiviral drug susceptibility. J Virol Methods. 2007;140:25-31. (Pubitemid 46185592)
5. Hirsch HH, Brennan DC, Drachenberg CB, et al. Polyomavirus-associated nephropathy in renal transplantation: interdisciplinary analyses and recommendations. Transplantation. 2005;79:1277-1286.
6. Love TM, de Jesus R, Kean JA, et al. Activation of CREB/ATF sites by polyomavirus large T antigen. J Virol. 2005;79:4180-4190.
7. Rodriguez-Viciana P, Collins C, Fried M. Polyoma and SV40 proteins differentially regulate PP2A to activate distinct cellular signaling pathways involved in growth control. Proc Natl Acad Sci U S A. 2006;103:19290-19295.
8. Reiss K, Khalili K. Viruses and cancer: lessons from the human polyomavirus, JCV. Oncogene. 2003;22:6517-6523.
9. Eash S, Querbes W, Atwood WJ. Infection of Vero cells by BK virus is dependent on caveolae. J Virol. 2004;78:11583-11590.
10. Swimm AI, Bornmann W, Jiang M, et al. Abl family tyrosine kinases regulate sialylated ganglioside receptors for polyomavirus. J Virol. 2010;84:4243-4251.
11. Johnson LN. Protein kinase inhibitors: contributions from structure to clinical compounds. Q Rev Biophys. 2009;42:1-40.
12. Randhawa P, Zemlicka J, Sauerbrei A, et al. Anti-BK virus activity of nucleoside analogs. Antimicrob Agents Chemother. 2008;52:1519-1521. (Pubitemid 351522024)
13. Farasati NA, Shapiro R, Vats A, et al. Effect of leflunomide and cidofovir on replication of BK-virus in an in vitro culture system. Transplantation. 2005;79:116-118.
14. Randhawa P, Farasati NA, Huang Y. BK virus replication in vitro: limited effect of drugs interfering with viral uptake and intracellular transport. Antimicrob Agents Chemother. 2007;51:4492-4494.
15. Randhawa P, Farasati NA, Shapiro R, et al. Ether lipid ester derivatives of cidofovir inhibit polyomavirus BK replication in vitro. Antimicrob Agents Chemother. 2006;50:1564-1566.
16. Randhawa P, Shapiro R, Vats A. Quantitation of DNA of polyomaviruses BK and JC in human kidneys. J Infect Dis. 2005;192:504-509.
17. Eley T, Luo FR, Agrawal S, et al. Phase I study of the effect of gastric acid pH modulators on the bioavailability of oral dasatinib in healthy subjects. J Clin Pharmacol. 2009;49:700-709.
18. Hidalgo M, Siu LL, Nemunaitis J, et al. Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies. J Clin Oncol. 2001;19:3267-3279.
19. Thomas F, Rochaix P, Benlyazid A, et al. Pilot study of neoadjuvant treatment with erlotinib in nonmetastatic head and neck squamous cell carcinoma. Clin Cancer Res. 2007;13:7086-7092. (Pubitemid 350276892)
20. Swaisland H, Laight A, Stafford L, et al. Pharmacokinetics and tolerability of the orally active selective epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 in healthy volunteers. Clin Pharmacokinet. 2001;40:297-306.
21. Druker BJ, Talpaz M, Resta DJ, et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med. 2001;344:1031-1037.
22. Britten CD, Kabbinavar F, Hecht JR, et al. A phase I and pharmacokinetic study of sunitinib administered daily for 2 weeks, followed by a 1-week off period. Cancer Chemother Pharmacol. 2008;61:515-524.
23. Awada A, Hendlisz A, Gil T, et al. Phase I safety and pharmacokinetics of BAY 43-9006 administered for 21 days on/7 days off in patients with advanced, refractory solid tumours. Br J Cancer. 2005;92:1855-1861.
24. Strumberg D, Richly H, Hilger RA, et al. Phase I clinical and pharmacokinetic study of the novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors. J Clin Oncol. 2005;23:965-972.